Eventide Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$546K Buy
3,870
+583
+18% +$83.1K 0.01% 246
2026
Q2
$400K Buy
3,287
+492
+18% +$51.4K 0.01% 250
2026
Q1
$279K Buy
+2,795
New +$247K ﹤0.01% 253
2023
Q4
– Sell
-320,000
Closed -$5.34M – 165
2023
Q3
$5.34M Hold
320,000
– – 0.1% 134
2023
Q2
$8.84M Buy
+320,000
New +$8.01M 0.15% 123
2018
Q1
– Sell
-275,000
Closed -$5.72M – 148
2017
Q4
$5.72M Buy
275,000
+150,000
+120% +$2.66M 0.3% 81
2017
Q3
$2.21M Hold
125,000
– – 0.13% 100
2017
Q2
$1.41M Buy
+125,000
New +$1.34M 0.09% 103

Other funds holding PTGX

Eventide Asset Management's PTGX Position: Q3 2026 in Review

Eventide Asset Management increased its Protagonist Therapeutics (PTGX) stake by 18% in Q3 2026, buying an estimated $83.1K and bringing the position to 3,870 shares worth $546K. The position accounts for 0.01% of the portfolio, ranked #246.

Eventide Asset Management first reported a position in PTGX in Q2 2017 and has held it in 8 quarters since. The position peaked at $8.84M in Q2 2023. 328 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Eventide Asset Management held 3,870 shares of Protagonist Therapeutics worth $546K as of Q3 2026.
  • Eventide Asset Management bought 583 Protagonist Therapeutics shares in Q3 2026, an estimated $83.1K.
  • Protagonist Therapeutics made up 0.01% of Eventide Asset Management's portfolio in Q3 2026, its #246 holding.
  • Eventide Asset Management first reported a position in Protagonist Therapeutics in Q2 2017 and has held it in 8 quarters since.
  • Eventide Asset Management's Protagonist Therapeutics position peaked at $8.84M in Q2 2023.
  • 328 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.